| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Hainan Huluwa Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.69 |
| 52 Week High | CN¥20.09 |
| 52 Week Low | CN¥9.51 |
| Beta | 0.66 |
| 1 Month Change | -6.25% |
| 3 Month Change | 2.81% |
| 1 Year Change | -32.89% |
| 3 Year Change | -56.43% |
| 5 Year Change | n/a |
| Change since IPO | 56.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 605199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.2% | 5.6% | 3.1% |
| 1Y | -32.9% | -11.0% | -13.1% |
Return vs Industry: 605199 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 605199 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 605199 volatility | |
|---|---|
| 605199 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 605199 has not had significant price volatility in the past 3 months.
Volatility Over Time: 605199's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,083 | Jinping Liu | www.huluwayaoye.com |
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other therapeutic in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 605199 fundamental statistics | |
|---|---|
| Market cap | CN¥4.68b |
| Earnings (TTM) | CN¥94.97m |
| Revenue (TTM) | CN¥1.81b |
49.2x
P/E Ratio2.6x
P/S RatioIs 605199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605199 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.81b |
| Cost of Revenue | CN¥882.20m |
| Gross Profit | CN¥926.13m |
| Other Expenses | CN¥831.16m |
| Earnings | CN¥94.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 51.21% |
| Net Profit Margin | 5.25% |
| Debt/Equity Ratio | 108.0% |
How did 605199 perform over the long term?
See historical performance and comparison